Re: Campochiaro et al.: The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial (Ophthalmology. 2019;126:1141-1154)

Sharma Ashish; Kumar Nilesh; Kuppermann Baruch D.; Francesco Bandello

首页> 外文期刊>Ophthalmology >Re: Campochiaro et al.: The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial (Ophthalmology. 2019;126:1141-1154)

【24h】

Re: Campochiaro et al.: The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial (Ophthalmology. 2019;126:1141-1154)

机译：Re：Campochiasro等，Campochiasro等：与Ranibizumab进行新血管年龄相关性黄斑变性的港口递送系统：随机阶段2阶梯临床试验结果（眼科。2019; 126：1141-1154）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Ophthalmology》 |2019年第11期|共2页
作者
Sharma Ashish; Kumar Nilesh; Kuppermann Baruch D.; Francesco Bandello;
展开▼
作者单位

Lotus Eye Hosp &

Inst Dept Vitreoretina Coimbatore Tamil Nadu India;

Lotus Eye Hosp &

Inst Dept Vitreoretina Coimbatore Tamil Nadu India;

Univ Calif Irvine Gavin Herbert Eye Inst Irvine CA USA;

Univ Vita Salute Sci Inst San Raffaele Dept Ophthalmol Milan Italy;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类眼科学;
关键词

相似文献

外文文献
专利

1. Re: Campochiaro et al.: The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial (Ophthalmology. 2019;126:1141-1154) REPLY [J] . Campochiaro Peter A., Maass Katie F., Singh Natasha, Ophthalmology . 2019,第11期

机译：Re：Campochiaro等：携带新血管年龄相关黄斑变性的Ranibizumab的端口递送系统：随机相2阶梯临床试验结果（眼科。2019; 126：1141-1154）回复
2. The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration Results from the Randomized Phase 2 Ladder Clinical Trial [J] . Campochiaro Peter A., Marcus Dennis M., Awh Carl C., Ophthalmology . 2019,第8期

机译：具有Ranibizumab的港口递送系统，用于随机相2阶梯临床试验的新生虫表现相关的黄斑变性结果
3. Re: Guymer et al.: Subthreshold nanosecond laser intervention in age-related macular degeneration: The LEAD Randomized Controlled Clinical Trial (Ophthalmology. 2019;126:829-838) [J] . Bhavsar Abdhish R., Baker Carl W. Ophthalmology . 2019,第12期

机译：Re：Guymer等人：亚阈值纳秒激光干预患者年龄相关性黄斑变性：铅随机对照临床试验（眼科。2019; 126：829-838）
4. Phase I clinical trial of a chlorhexidine diacetate intraoral delivery system in medically healthy gingivitis subjects. [D] . Van Scoyoc, Steven M. 2008

机译：在医学上健康的牙龈炎患者中，双乙酸洗必泰口服系统的I期临床试验。
5. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study [O] . Jennifer J. Arnold, Caroline M. Markey, Nicol P. Kurstjens, 2016

机译：视网膜下液在确定新生血管性年龄相关性黄斑变性患者治疗结果中的作用-雷珠单抗的IV期随机临床试验：FLUID研究
6. Re: Campochiaro et al.: The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial (Ophthalmology. 2019;126:1141-1154) [O] . Ashish Sharma, Nilesh Kumar, Baruch D. Kuppermann, 2019

机译：Re：Campochiasro等，Camochochias等：与ranibizumab的港口递送系统用于新生血管年龄相关的黄斑变性：随机相2阶梯临床试验结果（眼科。2019; 126：1141-1154）

Re: Campochiaro et al.: The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial (Ophthalmology. 2019;126:1141-1154)

著录项

相似文献

相关主题

期刊订阅